[view original post] Acurx Pharmaceuticals’ (NASDAQ: ACXP) competitive position in the race to bring an effective treatment against C. difficile (CDI) just got stronger. … Continue reading Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)